miR-506: A regulator of chemo-sensitivity through suppression of the RAD51-homologous recombination axis

Chinese Journal of Cancer

Volumn 34, Issue 11, 2015, Pages

  Liu, Guoyan ^a   Xue, Fengxia ^a   Zhang, Wei ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Drug sensitivity; Homologous recombination; MicroRNA 506; RAD51; Synthetic lethality

Indexed keywords

BRCA2 PROTEIN; CISPLATIN; MICRORNA; MICRORNA 506; NANOPARTICLE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; RAD51 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PIPERAZINE; PIPERAZINE DERIVATIVE;

3' UNTRANSLATED REGION; CANCER CELL; CHEMOSENSITIVITY; DNA STRAND BREAKAGE; DRUG RESPONSE; EPITHELIAL MESENCHYMAL TRANSITION; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENE REPRESSION; GENE TARGETING; GENETIC RECOMBINATION; HOMOLOGOUS RECOMBINATION; HUMAN; NONHUMAN; NOTE; OVARY CARCINOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; ANIMAL; COMBINATION DRUG THERAPY; DISEASE FREE SURVIVAL; DRUG RESISTANCE; FEMALE; MOUSE; OVARY TUMOR; PROGNOSIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; HOMOLOGOUS RECOMBINATION; HUMANS; MICE; MICRORNAS; OVARIAN NEOPLASMS; PIPERAZINES; PROGNOSIS; RAD51 RECOMBINASE;

EID: 84947425754     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.1186/s40880-015-0049-z     Document Type: Note

References (18)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
2. Devouassoux-Shisheboran M, Genestie C. Pathobiology of ovarian carcinomas. Chin J Cancer. 2015;34(1):50–5.
3. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15.
4. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 2011;12(1):68–78.
5. Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, et al. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst. 2015;107(7). doi:10.1093/jnci/djv108
6. Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013;23(2):186–99.
7. Liu G, Sun Y, Ji P, Li X, Cogdell D, Yang D, et al. MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol. 2014;233(3):308–18.
8. Sun Y, Guo F, Bagnoli M, Xue FX, Sun BC, Shmulevich I, et al. Key nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancer. Chin J Cancer. 2015;34(1):28–40.
9. Baumann P, West SC. Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci. 1998;23(7):247–51.
10. Quiros S, Roos WP, Kaina B. Rad51 and BRCA2—new molecular targets for sensitizing glioma cells to alkylating anticancer drugs. PLoS One. 2011;6(11):e27183.
11. Tsai MS, Kuo YH, Chiu YF, Su YC, Lin YW. Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells. J Pharmacol Exp Ther. 2010;335(3):830–40.
12. Ito M, Yamamoto S, Nimura K, Hiraoka K, Tamai K, Kaneda Y. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med. 2005;7(8):1044–52.
13. Yang Z, Waldman AS, Wyatt MD. Expression and regulation of RAD51 mediate cellular responses to chemotherapeutics. Biochem Pharmacol. 2012;83(6):741–6.
14. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21.
15. Chen A. PARP inhibitors: its role in treatment of cancer. Chin J Cancer. 2011;30(7):463–71.
16. Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011;306(14):1557–65.
17. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 2012;307(4):382–90.
18. Liu G, Yang D, Sun Y, Shmulevich I, Xue F, Sood AK, et al. Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. Pharmacogenomics. 2012;13(13):1523–35.